Status:
RECRUITING
Reversing Glucose and Lipid-mediated Vascular Dysfunction
Lead Sponsor:
University of Kansas Medical Center
Conditions:
Blood Pressure
Hypertension
Eligibility:
All Genders
18-79 years
Phase:
EARLY_PHASE1
Brief Summary
The purpose of our study is to understand the extent to which the blood vessels are affected by glucose and fat (lipids) in lean healthy adults and if these changes in the blood vessels contribute to ...
Detailed Description
Hypertension, obesity, and insulin resistance are associated with elevated muscle sympathetic nerve activity (MSNA), which is important for blood pressure regulation. The measurement of MSNA is safely...
Eligibility Criteria
Inclusion
- Lean: BMI \< 25 kg/m
- Normal insulin sensitivity: (calculation based on fasting glucose and insulin concentrations in blood)
- Middle-aged: 18-79 years
- Blood pressure: \< 140 (systolic) and \< 90 mmHg (diastolic
- Weight stable (+/- 5 lbs) for the previous 3 months
- Participants must be willing and able to discontinue taking any vitamin C or E supplements or omega-3 fatty acids beginning 2 weeks prior.
- Able and willing to provide written informed consent
Exclusion
- Diabetes mellitus Type I or Type II: fasting glucose \< 126 mg/dL and/or HbA1c \< 6.5%
- Current smoker or History of smoking in the past 3 months.
- Hyperlipidemia: Fasting triglycerides \< 250 mg/dL
- Hypertension: \>130/80 mmHg
- History of heart disease (e.g., myocardial infarction, stent, heart attack, stroke, heart failure, valvular heart disease, cardiomyopathy)
- History of vascular disease (e.g., bypass, stroke)
Key Trial Info
Start Date :
May 9 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2027
Estimated Enrollment :
46 Patients enrolled
Trial Details
Trial ID
NCT04832009
Start Date
May 9 2022
End Date
August 1 2027
Last Update
June 5 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Kansas Medical Center
Kansas City, Kansas, United States, 66103